Navigation Links
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
Date:8/21/2008

Phase II Lucanix(R) study and the investigator-initiated Phase II trial.

"This is a very promising approach to cancer treatment, and results reported so far are beyond anyone's expectations. I am very excited to be a part of this confirmatory effort, and to be able to offer this unique treatment option to my patients," said Dr. Lyudmila Bazhenova, principal investigator of the STOP trial at the Rebecca and John Moore's Cancer Center of UCSD. "Traditional chemotherapy for stage IV NSCLC still yields disappointing results, and my hope is that this trial will improve the natural history of the disease." The FDA granted NovaRx Fast-Track approval for the Lucanix(R) trial in March of 2007, and Special Protocol Assessment approval in January of 2008.

According to the American Cancer Society, in 2008 there will be an estimated 215,000 new cases of lung cancer diagnosed, and 162,000 deaths caused by this disease in the United States alone. Lung cancer is the number one cause of cancer death throughout the world. "The statistics for global lung cancer deaths are staggering. I am confident that this Phase III trial will establish Lucanix(R) as a viable treatment option for patients with this dreaded disease," said Dr. Habib Fakhrai, president and co-founder of NovaRx.

In Phase II testing, 50 percent of patients entering the trial with stable disease who received Lucanix(TM) following one frontline regimen of chemotherapy lived more than 44 months, compared to less than 10-12 months for such patients under the current standard of care. In addition, patients with advanced disease who received Lucanix(TM) after zero to five prior chemotherapy treatments demonstrated a one-year survival of 61 percent and a two-year survival of 41 percent. Such late-stage patients typically demonstrate one-year survival of less than 30 percent. Lucanix(TM) was shown to produce only insignificant side effects.

"In addition to significantly increased survival," Fakhrai co
'/>"/>

SOURCE NovaRx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
5. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
6. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
7. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
8. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
9. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 BioPlus ... leading specialty pharmacies, has an expanded team of ... pharmacy consultants for prescriber offices in their regions, ... , “We have a variety of Regional Pharmaceutical ... those specializing in hepatitis C help prescribers understand ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that ... Board, to succeed Donald Fresne ; Mr. Fresne has ... a member of the Board.  In recognition of the many ... over almost twenty years, the Board designated Mr. Fresne as ... established a Search Committee to find a suitable replacement with ...
(Date:12/17/2014)... 2014 “Never say, ‘I cannot ... Marburg’s Department of Physics, advises young women pursuing ... released SPIE Women in Optics 18-month planner ... to ask questions.” , In the annual planner, ... occupations ranging from university professor and laboratory researcher ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... and SEATTLE, Jan. 5, 2012 CMC Biologics, ... issuance of European Patent No. US 2,171,034 B1 ... fermentations and mammalian cell culture bioreactors. The invention ... in a continuous perfusion fermentation process, wherein the ...
... Technologies Corporation (NASDAQ: LIFE ) has ... de Normalisation (AFNOR) for its MicroSEQ® Listeria ... assays, molecular tests that are designed to ... this food-borne pathogen that most recently has been associated ...
... SYDNEY, Jan. 4, 2012 The Company today announced that ... ("ADR") program.  The previous conversion ratio of 5 Novogen Limited ... Novogen Limited ordinary shares for each ADR share.  The change ... the ADR ratio will have no effect on the number ...
Cached Biology Technology:CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems 2Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 2Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 3Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 4
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Hippocampus adapts to environmental stresses, Stockpiles ... under favorable conditions, Knowledge of how neural stem cells ... diseases such as Alzheimer,s and Parkinson,s ... known for years that neurogenesis takes place throughout adulthood ...
... German . , The brains of all vertebrates ... the brain areas that control their singing behaviour could be ... songbird species, only the males sing and indeed, they do ... However, even species where both sexes sing identically, display the ...
... It sounds like something out of a comic book ... but that is exactly what two investigators at the Wellman ... In a report that will appear in the journal ... researchers Malte Gather, PhD, and Seok Hyun Yun, PhD, describe ...
Cached Biology News:Brain structure adapts to environmental change 2Birdsong independent of brain size 2Birdsong independent of brain size 3Single GFP-expressing cell is basis of living laser device 2Single GFP-expressing cell is basis of living laser device 3
...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Human PDGF, CF...
... ultimate in utility and flexibility press-to-seal silicone ... needs of the researcher. They are available ... as sheet material that can be easily ... are autoclavable and non-cytotoxic and can be ...
Biology Products: